Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
REGULATORY
Japan Panel to Weigh Keytruda SC, J&J Psoriasis Pill among 6 NMEs on Aug. 24
Quick Look: Six NMEs are up for MHLW panel review on August 24: Keytruda SC, J&J’s Icotyde, Sobi’s Gamifant, Ipsen’s Ojemda, Takeda’s Elahere, and Ohara’s Modeyso. The session will also cover broader labels for Skyrizi and Tevimbra, while Meiji’s Stelara…
To read the full story
Related Article
- Keytruda SC Heads to Japan Approval, Ipsen’s Ojemda for Conditional Nod
August 25, 2026
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
- J&J Files Tecvayli/Darzquro Combo for MM in Japan
February 12, 2026
- Ohara Files Japan NDA for Jazz’s Diffuse Midline Glioma Drug
February 2, 2026
- Takeda Files ImmunoGen-Paired ADC for Ovarian Cancer in Japan
February 2, 2026
- Japan Panel Green-Lights Pfizer’s Tukysa, Wider Labels for Tezspire, and More Drugs
January 30, 2026
- J&J Files Oral Psoriasis Drug Icotrokinra in Japan
November 10, 2025
- MSD Seeks Capvaxive Use in High-Risk Children in Japan
November 10, 2025
- Genmab Seeks Label Expansion for Epkinly Combo Use in Japan
November 7, 2025
- MSD Files for Keytruda Label Expansion in Ovarian Cancer
October 31, 2025
- AbbVie Files Skyrizi for Pediatric Dosage in Japan
October 30, 2025
- Enhertu Combo Filed for First-Line HER2 Breast Cancer in Japan
October 8, 2025
REGULATORY
- Kyowa Kirin’s Libmeldy Gene Therapy Now in Line for Japan Approval
November 10, 2026
- Astellas Employee Jailed for Espionage in China Set for December Release
November 10, 2026
- Nearly 1,200 COVID Vaccine Injury Relief Claims Still Await Review in Japan
November 10, 2026
- LDP League Seeks Drug Pricing Revamp to Support Patches
November 10, 2026
- Keytruda SC Tops New NHI Listing Round with 75 Billion Yen Sales Outlook
November 9, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…